Back to Leadership

David E.I. Pyott

  • Director, Alynlam Pharmaceuticals, Inc.
  • Director, Pliant Therapeutics, Inc.
  • Supervisory Board Member, Royal Philips in the Netherlands

Committees:

  • Compensation
  • Corporate Governance and Nominating

LinkedIn

David E.I. Pyott, M.D. (Hon.), joined BioMarin’s Board of Directors in January 2016 and serves as Chair of the Corporate Governance and Nominating Committee.

Dr. Pyott served as Chief Executive Officer of Allergan, Inc. from 1998 to March 2015. Prior to Allergan, Dr. Pyott served as the Head of the Novartis Nutrition Division and a member of the Executive Committee of Novartis AG.

Dr. Pyott serves on the boards of Alnylam Pharmaceuticals, Inc. and Pliant Therapeutics, Inc. He is also a member of the Supervisory Board of Royal Philips in the Netherlands. Additionally, he is Chairman of the Governing Board of the London Business School, a member of the Board of Trustees of the California Institute of Technology and a Vice-President of the Ophthalmology Foundation. Dr. Pyott served as Lead Director at Avery Dennison Corporation until April 2020.

Dr. Pyott holds a Diploma in International and European Law from the Europa Institute at the University of Amsterdam, an Honorary Degree in Medicine and an M.A. degree from the University of Edinburgh, and an M.B.A. degree from the London Business School.